Drug Profile

Prostate cancer subunit vaccine - Progenics

Alternative Names: Recombinant soluble PSMA protein vaccine; rsPSMA

Latest Information Update: 30 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Memorial Sloan-Kettering Cancer Center
Developer Progenics Pharmaceuticals
Class Cancer vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Prostate cancer

Most Recent Events

30 Jan 2025 Phase I development is ongoing for Prostate cancer in USA (Alphavax pipeline, January 2025)
28 Apr 2023 No recent reports of development identified for phase-I development in Prostate-cancer in USA (SC)
22 Apr 2021 Phase-I development is ongoing for Prostate cancer in the US (Alphavax pipeline, April 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com